Editor-in-Chief
Professor Joan M. Cranmer
Editor-in-Chief, NeuroToxicology
Department of Pediatrics of ACH
University of Arkansas for Medical Sciences
800 Marshall St., Suite 304
Little Rock, AR 72202, USA
Tel: +1-501-364-2986
Fax: +1-501-364-4978
E-mail: CranmerJoanM@uams.edu
NeuroToxicology specializes in
publishing the best peer-reviewed original research papers dealing with the effects of toxic substances on the nervous system of humans
and experimental animals of all ages. The Journal emphasizes papers dealing with the neurotoxic effects of environmentally significant
chemical hazards, manufactured drugs and naturally occurring compounds. Papers dealing with the effects of neurotoxicants on
other systems (e.g., reproductive, endocrine, immune) or processes (e.g., metabolic) are also welcome.
NeuroToxicology
recognizes the diverse backgrounds and interests of scientists who work in these areas and encourages the participation of all.
Areas of special emphasis and interest -- both basic and applied -- have been identified; they include: neuropathology, neurophysiology,
neurochemistry, neuropharmacology, neurology, behavioral toxicology, development neurotoxicology, psychiatry, toxicology, epidemiology,
psychology, neuroteratology, behavioral teratology, risk assessment and regulatory issues. Papers reporting interdisciplinary studies
are especially welcome. Papers reporting any effects of known neurotoxicants are welcome.
NeuroToxicology will publish
papers containing Original Research, Brief Communications, Reviews, Letters to the Editor, Teaching Monographs, Forum "Position Papers,"
Commentaries, Book Reviews, and Features. Periodically, the Journal will also publish Announcements, Abstracts
and Proceedings of Meetings.
Original Research. Articles will contain laboratory or clinical scientific research pertaining
to neurotoxicology. Economy of style is encouraged, although papers may be as long as short as the findings justify. Illustrations should
make significant points. Excessive or repetitive illustrations will not be published.
Brief Communications.NeuroToxicology
will publish brief reports of work that has progressed to the stage at which it is considered that the science of neurotoxicology would
be advanced if the results were made available as soon as possible. These reports should be no longer than six pages in the present format
of NeuroToxicology. Authors should submit reports of this category of publication only when they believe that the rapid world-wide
communication of the results is of the utmost importance to other investigators.
Reviews. Review papers will summarize and
critically analyze topics of current interest in neurotoxicology. Authors should keep in mind the diverse backgrounds of the readers
of this interdisciplinary Journal.
Letters to the Editor. Letters to the Editor may be up to 500 words in length,
responding to material in NeuroToxicology, introducing a new point of view, or discussing a topic of current concern. Letters
will be subject to the same review process as Original Research articles and Reviews. Any letter responding to a previous
publication may be submitted to the author of the original paper in order that any reply may be published simultaneously with the letter.
Letters should be received within two months of mailing of the Journal.
Teaching Monographs. The format and length
of monographs will be the prerogative of the author. The subject matter should be of broad
interest due to the diverse backgrounds of
the readership. The contents should be aimed at the level of a senior graduate student in neurosciences or toxicology. Teaching illustrations
are encouraged.
Forum. The Forum section "Position Papers" of the Journal will address, discuss, and present position
papers on current issues in neurotoxicology. Replies will be invited from all sectors of society; they include: chemical industries,
pharmaceutical industries, governmental regulatory agencies, other governmental groups, academic institutions, as well as consumers and
special interest groups. The format will be flexible. Letters responding to a position paper in the Forum section will be submitted to
the author of the position paper in order that any reply may be published simultaneously with the Letter. Letters should be received
within two months of mailing of the Journal.
Announcements, Abstracts, Proceedings.NeuroToxicology will
accept for publication announcements, abstracts, or capsulized proceedings of meetings, symposia or other matters of interest to the
subscriber of NeuroToxicology.
Conflict of interest.NeuroToxicology requires full disclosure of all potential
conflicts of interest. At the end of the manuscript text (and in the cover letter of the manuscript), under a subheading "Conflict of
Interest statement", all authors must disclose any financial and personal relationships with other people or organisations that could
inappropriately influence (bias) their work. If there are no conflicts of interest, the authors should state, "The authors declare that
there are no conflicts of interest." Signed copies of the NeuroToxicology Conflict of Interest policy form are required upon
submission. The Conflict of Interest policy form can be downloaded here.
In order to minimize delays, we strongly advise that the signed copies of these statements are prepared before you submit your manuscript.
The corresponding author is responsible for sharing this document with all co-authors. Each and every co-author must sign an individual
disclosure form. The corresponding author is responsible for uploading their form and those of their co-authors.
Submission of
Manuscripts.It is a condition of publication that all manuscripts must be submitted in English to NeuroToxicology's submission and
review website, http://ees.elsevier.com/neutox. Authors are requested to transmit the text and art of the manuscript in
electronic form to this address. Minimal exceptions will be exercised. Should you be unable to provide an electronic version, please
contact the editorial assistants prior to submission.
Submissions considered for publication are received with the understanding that
they have not previously appeared elsewhere in any but abstract form and are not simultaneously being submitted to another journal. All
articles are subject to review by two or more experienced referees. Decisions of the Editor-in-Chief are final.
General Points.
Enclose a covering letter indicating the corresponding author and provide address, telephone, fax number and e-mail address. For manuscripts
dealing with experimental work involving human subjects, specify that informed consent was obtained following a full explanation of the
procedures to be undertaken.
Original Articles should be divided into headed sections in the following order: Title Page
(Page 1), Abstract and Key Words, Introduction, Materials and Methods, Results, Discussion (and Conclusions), Acknowledgments, References,
Tables and Figure Legends. Letters should contain no headings, but a title may be suggested. Form for Reviews and Teaching
Monographs will be left to the discretion of the author.
Title Page. Page 1 of the manuscript should contain the title
(upper case), the name(s) of author(s), institutional affiliation(s) of author(s), name and mailing address, telephone, fax number and
e-mail address of person(s) receiving reprints.
Abstract Page. For Research papers only. Page 2 should contain a concise
summary not to exceed 300 words. A list of 3-6 key words or short phrases suitable for indexing terms should be typed at the bottom of
the Abstract Page.
Footnotes. Avoid or use sparingly. Identify in the text with superscript numerals, numbered consecutively.
Copy for footnotes should be typed double-spaced and inserted immediately after the Abstract Page.
Materials and Methods.
Avoid excessively detailed description and unnecessary literature citations of widely used techniques. Instead, explain concisely and
briefly each method, aiming to reach the broad readership of Journal. Delineate new procedures in full. State source of all materials
under investigation and, if applicable, the exact strain and source of animal used.
Results. Describe experimental and control
data obtained. Present data in tabular or graphic form where possible. Do not describe illustrations in text or repeat text information
in figure legend(s).
References. Cite authors in text as follows: e.g. (Woolley, 1973), (Schneider and Norton, 1974), (Takeuchi
et al., 1974), (Griffin et al., 1973a,b.) List in alphabetical order, double-spaced, starting on a separate page.
Lowry OH, Rosebrough
NJ, Farr AL, Randal RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-75
Armitage P. Statistical methods
in medical research. New York: John Wiley and Sons, Inc., 1971.p. 380-84
Martinez AJ, Taylor JR, Houff SA, Isaacs ER. Kepone poisoning:
clinico-neuropathological study. In: Neurotoxicology, Roizin L, Shriraki H, Greevic N., editors. New York: Raven Press, 1977.p.
443-56
Tables. Tables should be numbered and headed with short titles. Tables should be typed on separate sheets and the
preferred point of insertion noted in the text by listing the table number in the left hand margin. No tables too large to be printed
on one page should be included.
Figures.Each figure should be in one of the following preferred formats: Tiff, JPEG,
PDF, and EPS. Please refer to http://www.elsevier.com/artworkinstructions for detailed instructions on preparing electronic
artwork.
Nomenclature. For styling of isotope, enzyme, and biochemical nomenclature, consult the Information for Authors
of the Archives of Biochemistry and Biophysics.
Units and Abbreviations. Units will be in general accordance with
the International System (SI) as adopted by the 11th General Conference on Weights and Measures. Note that the abbreviations for a unit
is never followed by a full stop, e.g. 10glL, 5 pmpl, 2mM. Do not use full stops in abbreviations with capital letters, e.g. DNA. For
case abbreviations use full stops, e.g. i.v.,s.c. All other words to be abbreviated should be written in full when they appear in the
text and be followed by the abbreviation in parentheses.
Reprints. Reprints may be ordered with the form which accompanies
final page proofs.
US National Institutes of Health (NIH) voluntary posting (" Public Access") policy.
Elsevier facilitates author
response to the NIH voluntary posting request (referred to as the NIH "Public Access Policy"; see http://www.nih.gov/about/publicaccess/index.htm) by posting the peer-reviewed author's manuscript directly to PubMed Central on request from the author,
12 months after formal publication. Upon notification from Elsevier of acceptance, we will ask you to confirm via e-mail (by e-mailing
us at NIHauthorrequest@elsevier.com ) that your work has received NIH funding and that you intend to respond to the NIH
policy request, along with your NIH award number to facilitate processing. Upon such confirmation, Elsevier will submit to PubMed Central
on your behalf a version of your manuscript that will include peer-review comments, for posting 12 months after formal publication. This
will ensure that you will have responded fully to the NIH request policy. There will be no need for you to post your manuscript directly
with PubMed Central, and any such posting is prohibited.
Authors enquiries. Authors can keep a track of the progress of their
accepted article including questions relating to proofs, publication and offprints on the Internet on our Guide for Authors (go to http://www.elsevier.com/authors)
or email authorsupport@elsevier.com
Authors of NeuroToxicology please note: there is no page charge for this journal.
